Global

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Cardiac amyloidosis is no longer the whole story of protein misfolding

ESCAT v2 Makes Resistance Clinically Actionable

Endometrial Cancer Gets a Strong ADC Win

A filter can blunt pollution’s cardiac effects. It cannot be the policy

Divarasib Raises the KRAS G12C Bar

Cardiovascular prevention has a climate blind spot

Cardiovascular prevention has a climate blind spot

Lifelong exercise protects the heart. It can also make the heart harder to read

If BMI misses cardiovascular risk, why is policy still built around it?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
